Cooper Companies (COO)
Health Care · $10.4B market cap · SEC CIK 0000711404
fundamentals score out of 100
Next reports on Mar 3, 2027, with analysts expecting $1.11 in earnings per share.
The case for COO
- Earnings per share up 44.2%.
- A PEG of 0.41: a P/E of 18.2× is low for EPS growing 44%.
- Has compounded revenue at 11.0% a year over five years.
- Gross margin of 66% absorbs cost shocks.
The case against
- Down 20.6% over the past year.
- Return on equity of only 7%.
- Near the bottom of its 52-week range, 38% below the high. Falling prices usually have a reason; find it first.
- Long-term debt of $1.9B against $125M of cash.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 73 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 72 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 55 |
| Momentumhow the price has behaved lately | 18 |
| Stabilityhow violently it moves, what it owes and what it pays you | 48 |
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
Key numbers
| Price / earnings | 18.2× |
|---|---|
| Price / book | 1.69× |
| Price / sales | 2.4× |
| Revenue growth (YoY) | +4.7% |
| EPS growth (YoY) | +44.2% |
| Gross margin | 66% |
| Operating margin | 13% |
| Net margin | 13% |
| Return on equity | 7% |
| Debt / equity | 0.31× |
| Current ratio | 1.22 |
| Dividend yield | 0.02% |
| Beta | 0.82 |
| 52-week range | $51.01 – $89.83 |
| Position in that range | 11% of the way up |
| 3-month return | -17.9% |
| 1-year return | -20.6% |
Five years of financials, as filed
Pulled from Cooper Companies's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $4.1B | $3.9B | $3.6B | $3.3B | $2.9B |
| Gross profit | $2.7B | $2.6B | $2.4B | $2.1B | $2.0B |
| Operating income | $683M | $706M | $533M | $508M | $506M |
| Net income | $375M | $392M | $294M | $386M | $2.9B |
| Operating cash flow | $796M | $709M | $608M | $692M | $739M |
| Capital expenditure | $362M | $421M | $393M | $242M | $214M |
| Total assets | $12.4B | $12.2B | $12.0B | $11.6B | $11.7B |
| Total liabilities | $4.1B | $4.1B | $4.3B | $4.2B | $4.7B |
| Shareholder equity | $8.4B | $8.1B | $7.7B | $7.3B | $6.9B |
| Cash | $125M | $101M | $135M | $118M | $281M |
| Long-term debt | $1.9B | $2.5B | $2.7B | $2.6B | $2.3B |
| Free cash flow | $434M | $288M | $215M | $450M | $524M |
| Gross margin | 65.5% | 66.6% | 65.6% | 64.7% | 66.9% |
| Operating margin | 16.7% | 18.1% | 14.8% | 15.3% | 17.3% |
| Net margin | 9.2% | 10.1% | 8.2% | 11.7% | 100.8% |
| Diluted shares | 200M | 200M | 199M | 199M | 199M |
Share count is essentially flat over 4 years. Counts are restated for stock splits so the years compare.
What Cooper Companies says it does
OVERVIEW The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year. Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and women’s health. For financial information relating to these business segments, refer to Note 12. Business Segment Information in Item 8. Financial Statements and Supplementary Data of this Annual Report. CooperVision is a global manufacturer providing products for contact lens wearers. CooperVision develops, manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and…
Risk factors COO lists in its 10-K
- Our substantial and expanding international operations are subject to uncertainties which could affect our business
- We are vulnerable to interest rate risk with respect to our debt
- Financial Statements and Supplementary Data
- Report of Independent Registered Public Accounting Firm
- Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting
- Internal Control – Integrated Framework (2013)
- Definition and Limitations of Internal Control Over Financial Reporting
- Evaluation of the sufficiency of audit evidence over inventories and net sales
- (In millions, except for earnings per share)
- Consolidated Statements of Comprehensive Income
- Consolidated Statements of Stockholders' Equity
- Accumulated Other Comprehensive Income Loss
- (In millions, except per share amounts)
- Consolidated Statements of Cash Flow